Precision medicine identifies differences in people’s genes, environments and lifestyles conferring each patient tumor a different behavior. With MAF FISH test insight, informed decisions tailored to each patient can be made.  Recent clinical studies have determined that amplification of MAF gene in tumoral cells of breast cancer is associated with increased risk of bone metastasis.

MAF-Test® measures the amplification of the MAF gene in the tumoral cells.

MAF amplification occurs in 20% of breast cancer tumors and is associated with a higher risk of patient disease progression.

For patients with early-stage (I, II, or III), that is either node-negative or node-positive (1-3 nodes).